Embryopathic effects of short-term exposure to hypoglycemia in mouse embryos in vitro

Glucose causes lengthening of the microvilli of the neural plate of the rat embryo and produces a helical pattern on their surface

Prominent microvilli have been observed on the surface of neural plates in the embryos of many species. Since glucose is the main source of energy for embryos before neural tube closure and the onset of vascular circulation, it was of interest to study the relationship between these microvilli and glucose utilization in the neural plate. By applying microdrops of amniotic fluid to chemstrips, which colorimetrically measure glucose by glucose oxidase reaction, we determined that day 10 rat amniotic fluid glucose level was 31.6 +/- 1.6 mg/dl. On day 10 and within about 20 min from removal of the decidual sites, no glucose was found in the amniotic fluid. By use of a scanning electron microscope, the microvilli of the day 10 neural plate were found to have a 10-fold increase in length during a 40-min exposure to Hanks' solution at 21-23 degrees C. Similarly exposed embryos in Hanks' without glucose did not have microvillus elongation. However, under whole embryo culture conditions at 38 degrees C no extension of the microvilli was found. In the closed neural tube of the day 10 embryo, the microvilli were stubby and did not elongate with glucose exposure. Similarly, day 11 and 14 embryos had short microvilli which did not elongate with direct exposure to glucose at 21-23 degrees C. The short microvilli on the surface of the closed neural tube on day 11, 14, and 16 were associated with low glucose concentrations in the neural tube fluids. By use of a field emission scanning electron microscope, the surfaces of the microvilli in the extended position were seen to be covered by a right-handed helical array of globular objects the size of large molecules. The findings support the hypothesis that microvillar length may modulate glucose uptake. Shortening is associated with low concentrations of glucose in closed neural tubes, and lengthening occurs at glucose exposures of 100 mg/dl.

Effects of altered maternal metabolism during gastrulation and neurulation stages of embryogenesis

In summary, many congenital malformations are produced during gastrulation and neurulation stages of embryogenesis at a time when no definitive chorioallantoic placenta has been established. In rodents, altered maternal metabolism may have a direct impact on the embryo or an indirect impact via disruption of the nutritive function of the visceral yolk sac. If similar mechanisms operate in human embryos, these factors probably alter functions of the trophoblastic shell. In any case, it is crucial to remember that the metabolic status of the embryo is rapidly changing and during early stages of organogenesis may respond to alterations in nutrients quite differently during the first four weeks of gestation than at later stages of organogenesis and the fetal period.

Teratogenic effects of tolbutamide on early-somite mouse embryos in vitro

The present study investigated the teratogenicity of the oral hypoglycemic agent, tolbutamide, using an in vitro approach, and evaluated the role of its main metabolic effect, hypoglycemia. Teratogenesis was evaluated by culturing early-somite mouse embryos for 24 h in serum from rats treated with tolbutamide (79-117 micrograms/ml) or normal rat serum supplemented with tolbutamide (110-152 micrograms/ml). Tolbutamide-treated serum was then supplemented with glucose to control for potential effects of hypoglycemia. Mouse embryos demonstrated high malformation rates following exposure to serum from tolbutamide-treated rats (79%) or normal rat serum supplemented with tolbutamide (85%) compared with controls (4%), and defects included cardiac, ocular, neural tube, and somite abnormalities. Overall growth was reduced in treated embryos and yolk sacs, as determined by total protein contents. Embryonic growth and malformation rates were not improved by glucose supplementation of hypoglycemic tolbutamide-treated serum. Thus, tolbutamide produces malformation in mouse embryos in vitro at concentrations comparable to those in human serum, and the effects do not appear to be mediated by hypoglycemia. The potential risk of tolbutamide on the developing embryo must be considered in the therapy of pregnant diabetic patients.

Hypothermia: teratogenic and protective effects on the development of mouse embryos in vitro

Hypothermia often occurs in association with clinical conditions involving severe hypoglycemia, but its effect on embryonic development has not been well evaluated. Thus, the whole embryo culture method was used to expose day 9 (neurulating) and day 10 (early limb bud stage) mouse embryos to physiologic levels of hypothermia (35 degrees C and 32 degrees C) for 4 and 24 hr. Embryos were evaluated after 24 hours for growth and malformations and compared with controls grown at 37 degrees C. Lactate production was measured in embryos cultured for 4 hr at 32 degrees C and compared with those cultured at 37 degrees C. A 4-hr exposure to hypothermia produced little effect morphologically but reduced the rate of lactate production at both embryonic stages. A 24-hr exposure to hypothermia at 35 degrees C or 32 degrees C produced growth retardation and dysmorphogenesis in embryos undergoing neurulation. Early limb bud stage embryos were less sensitive to this treatment, with growth retardation produced only at the lower temperature. Since hypothermia is commonly associated with severe hypoglycemia in cases of diabetic insulin overdose, day 9 (neurulating) mouse embryos were exposed concurrently to short periods of hypothermia and hypoglycemia and compared with embryos cultured in hypoglycemic medium at normal temperature. The results demonstrate that hypothermia partially protects embryos against the dysmorphogenic effects of hypoglycemia. A balance of metabolic rate and available substrate is discussed as a possible mechanism for this protective effect.